Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.34 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29163121 | 0.90 | NPC1 (0.47) | NPC1RAB9ATBXAS1KMT2AKDM4E | |
| Malonic Acid SCHEMBL28603419 | 0.84 | NPC1 (0.43) | NPC1RAB9ATBXAS1KMT2AKDM4E | |
| SCHEMBL5163628 | 0.82 | NPC1 (0.42) | NPC1RAB9ATBXAS1KMT2AKDM4E | |
| SCHEMBL10997776 | 0.82 | TBXAS1 (0.49) | NPC1RAB9ATBXAS1KMT2AKDM4E | |
| Malonic Acid SCHEMBL27504201 | 0.81 | NPC1 (0.41) | NPC1RAB9ATBXAS1KMT2AKDM4E | |
| SCHEMBL31602536 | 0.81 | NPC1 (0.45) | NPC1RAB9ATBXAS1KMT2AKDM4E | |
| SCHEMBL9294432 | 0.79 | TBXAS1 (0.58) | NPC1RAB9ATBXAS1KMT2AGAA | |
| SCHEMBL5160052 | 0.79 | NPC1 (0.44) | NPC1RAB9ATBXAS1KMT2AKDM4E | |
| SCHEMBL5160738 | 0.79 | NPC1 (0.44) | NPC1RAB9ATBXAS1KMT2AKDM4E | |
| SCHEMBL5468184 | 0.79 | NPC1 (0.44) | NPC1RAB9ATBXAS1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2483283-B1 | Method for the manufacture of aminohydroxy diphosphonic acids | STRAITMARK HOLDING AG (CH) | 2015-01-07 | — | — | EP | claimed |
| US-8779135-B2 | Method for the manufacture of aminohydroxy diphosphonic acids | STRAITMARK HOLDING AG (CH) | 2014-07-15 | — | — | US | claimed |
| US-20120245354-A1 | METHOD FOR THE MANUFACTURE OF AMINOHYDROXY DIPHOSPHONIC ACIDS | STRAITMARK HOLDING AG (CH) | 2012-09-27 | — | — | US | claimed |
| EP-1476451-A1 | USE OF CERTAIN DILUENTS FOR MAKING BISPHOSPHONIC ACIDS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-11-17 | — | — | EP | claimed |
| WO-2003097655-A1 | USE OF CERTAIN DILUENTS FOR MAKING BISPHOSPHONIC ACIDS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-11-27 | — | — | WO | claimed |
| US-8940901-B2 | Process for the preparation of 3-(6-amino-pyridin-3yl)-2-acrylic acid derivatives | SANOFI (FR) | 2015-01-27 | — | — | US | disclosed |
| US-8865906-B2 | Process for the preparation of a compound useful as an inhibitor of TAFIa | SANOFI (FR) | 2014-10-21 | — | — | US | disclosed |
| EP-2638016-B1 | PROCESS FOR THE PREPARATION OF 3-(6-AMINO-PYRIDIN-3YL)-2-ACRYLIC ACID DERIVATIVES | SANOFI SA (FR) | 2014-10-01 | — | — | EP | disclosed |
| US-20130245274-A1 | Process for the preparation of 3-(6-amino-pyridin-3yl)-2-acrylic acid derivatives | SANOFI (FR) | 2013-09-19 | — | — | US | disclosed |
| EP-2638016-A1 | Process for the preparation of 3-(6-amino-pyridin-3yl)-2-acrylic acid derivatives | SANOFI (FR) | 2013-09-18 | — | — | EP | disclosed |
| EP-2430002-B1 | PROCESS FOR THE PREPARATION OF A COMPOUND USEFUL AS AN INHIBITOR OF TAFIA | SANOFI SA (FR) | 2013-07-24 | — | — | EP | disclosed |
| EP-2192126-B1 | Process for making zoledronic acid | SYNTHON BV (NL) | 2013-03-27 | — | — | EP | disclosed |
| EP-2192126-A1 | Process for making zoledronic acid | Synthon B.V. (NL) | 2010-06-02 | — | — | EP | disclosed |
| US-20100130746-A1 | Process for Making Zoledronic Acid | SYNTHON BV (NL) | 2010-05-27 | — | — | US | disclosed |
| EP-1987046-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF BIPHOSPHONIC DERIVATIVES | Alembic Limited (IN) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007096896-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF BIPHOSPHONIC DERIVATIVES | ALEMBIC LIMITED (IN) | 2007-08-30 | — | — | WO | disclosed |
| EP-1476451-A1 | USE OF CERTAIN DILUENTS FOR MAKING BISPHOSPHONIC ACIDS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-11-17 | — | — | EP | disclosed |
| WO-2003097655-A1 | USE OF CERTAIN DILUENTS FOR MAKING BISPHOSPHONIC ACIDS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-11-27 | — | — | WO | disclosed |
| EP-1089964-A1 | HYDRAZINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2001-04-11 | — | — | EP | disclosed |
| WO-2000000465-A1 | HYDRAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245274-A1 | Process for the preparation of 3-(6-amino-pyridin-3yl)-2-acrylic acid derivatives | C5, F5, F12 | NPC1 4413/4885RAB9A 2224/4885TBXAS1 652/4885 |
| US-20100130746-A1 | Process for Making Zoledronic Acid | PTH1R, CALCR, FGF23 | NPC1 682/4885RAB9A 1401/4885TBXAS1 1464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.